All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Aleksandr Lazaryan, MD MPH PhD, Moffitt Cancer Center, Tampa, US. We asked, How is survival impacted by belumosudil in chronic GvHD (cGvHD) which has failed prior therapy?
How is failure-free survival impacted by belumosudil in cGvHD which has failed prior therapy?
In this video, Lazaryan comments on belumosudil, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor. He also discusses the phase IIa study KD025-208 (NCT02841995), and the ROCKstar trial (NCT03640481).
ROCKstar: Belumosudil in chronic GvHD, an update from ASH 2021
Graft-versus-host disease (GvHD) is an immune-mediated disorder that can occur after a stem cell transplantation, whereby the T cells of the donor recognize the recipients’ cells as...
Positive topline results of belumosudil (KD025) in patients with chronic GvHD
On May 21, positive topline results of the pivotal trial evaluating belumosudil in patients with chronic graft-versus-disease (cGvHD) were announced.
Subscribe to get the best content related to GvHD delivered to your inbox